FDAAA Fading? REMS Use Continues To Decline As Drug Safety Law Matures
This article was originally published in RPM Report
FDA’s use of REMS continues to fall to almost undetectable levels, with the agency using the safety tools just a handful of times in the sixth full year of the program. REMS are now very much the exception and not the rule for new products – but still a very important exception.
You may also be interested in...
FDA hopes to begin accepting Risk Evaluation and Mitigation Strategy documents in structured product labeling format later this year.
Overwhelming votes against existing labels for the antibiotics likely means sponsors and FDA have some safety planning to do.
Joint advisory committee meeting will discuss post-marketing safety data, including adverse events across organ systems.